At 7.2% CAGR, the Asia Pacific Infectious Disease Diagnostics Market is Projected to be Worth US$ 8,165.77 Million by 2030, Says Business Market Insights

According to Business Market Insights' research, the Asia Pacific infectious disease diagnostics market was valued at US$ 4,673.02 million in 2022 and is expected to reach US$ 8,165.77 million by 2030, registering a CAGR of 7.2% from 2022 to 2030. Rising application of diagnostics in veterinary infectious disease and rising number of product approvals and launches are among the critical factors attributed to the Asia Pacific infectious disease diagnostics market expansion.

Veterinary infectious diseases negatively impact the health of domestic animals, livestock, and wildlife. As a result of intensive animal farming, there are conditions for the emergence and amplification of disease epidemics due to the genetic and physical proximity of the billions of animals, often in frail health, that are raised indoors every year. Moreover, animal farming contributes to the spread of infections from wild animals due to deforestation caused by the expansion of agricultural land use.

Diagnostic technologies that can detect emerging infectious animal diseases at an early stage are essential to reduce economic losses associated with outbreaks of such diseases. Polymerase chain reaction (PCR) remains the most widely used molecular assay globally to detect animal pathogens. Diagnostic methods of this type are easy to use, cost-effective, susceptible, and specific, with the ability to detect at a high volume.

Even though conventional virological methods are incredibly reliable, they are time-consuming and labor-intensive procedures. Lateral flow and enzyme-linked immunosorbent assay can be used for rapid detection. Multiplex bead immuno or Luminex assay is a fluorescent beads-based high-throughput quantitative technique used for the detection of multiple antibodies specific for different infectious diseases at the same time in a single reaction, leading to more rapid, economical, and accurate results compared with conventional ELISA. In addition, the protein chip based on surface plasmon resonance (SPR) appears to be a rapid valuable tool in the sero-diagnosis of infection or antibody titration. Recombinant antibodies can also be produced in heterologous systems by using rDNA technology and used for developing diagnostic tests.

Point-of-care diagnostics (POCDs) are simple, rapid, and portable diagnostic devices that can detect the disease status at the field level. In recent years, real-time PCR (qPCR) has been transitioned into a POCD platform. These fully automated platforms combine nucleic acid extraction, thermal cycling, and on-site reporting results. For instance, MiniLab from Enigma Diagnostics is a molecular diagnostic platform of 10-35 kg that is carried at the field level and used for validating African swine fever virus, classical swine fever virus, avian influenza virus, and foot-and-mouth disease virus for research purposes.

Similarly, Boster offers Bosterbio qPCR kits to detect up to 48 individual or pooled samples. It is used for gene expression profiling, target DNA quantification, microbial detection, viral or bacterial pathogen load determination, and evaluation of primer pair performance for probe-based qPCR. Thus, diagnostics methods such as PCR and qPCR to diagnose bacterial, viral, fungal, and parasitic infections in animals is fueling the diagnostics in veterinary diagnosis.

On the contrary, inadequate reimbursement scenario hampers the growth of Asia Pacific infectious disease diagnostics market.

Based on product, the Asia Pacific infectious disease diagnostics market is segmented into kits & reagents, instruments, and software & services. The kits & reagents segment held 68.2% share of the Asia Pacific infectious disease diagnostics market in 2022, amassing US$ 3,185.08 million. It is projected to garner US$ 5,472.90 million by 2030 to expand at 7.0% CAGR during 2022-2030.

By technology, the Asia Pacific infectious disease diagnostics market is segmented into biosensor-based, immunodiagnostics, molecular-based diagnostic techniques, clinical biology, and others. The molecular-based diagnostic techniques segment held 47.0% share of the Asia Pacific infectious disease diagnostics market in 2022, amassing US$ 2,197.00 million. It is projected to garner US$ 4,018.04 million by 2030 to expand at 7.8% CAGR during 2022-2030. The immunodiagnostics segment is further subsegmented into enzyme-linked immunosorbent assay (ELISA), western blotting analysis, and immunofluorescence assay. The molecular-based diagnostic techniques segment is further subsegmented into polymerase chain reaction (PCR), in situ hybridization, isothermal nucleic acid amplification technology (INAAT), next-generation sequencing (NGS), DNA microarrays, and others.

By application type, the Asia Pacific infectious disease diagnostics market is bifurcated into laboratory testing and point-of-care testing. The laboratory testing segment held 81.6% share of the Asia Pacific infectious disease diagnostics market in 2022, amassing US$ 3,813.06 million. It is projected to garner US$ 6,510.60 million by 2030 to expand at 6.9% CAGR during 2022-2030.

By testing type, the Asia Pacific infectious disease diagnostics market is bifurcated into human testing and veterinary testing. The human testing segment held 85.6% share of the Asia Pacific infectious disease diagnostics market in 2022, amassing US$ 3,998.32 million. It is projected to garner US$ 6,787.93 million by 2030 to expand at 6.8% CAGR during 2022-2030. The human testing segment is further subsegmented into HIV, hepatitis, HAIs, HPV, tuberculosis, influenza, and others.

By end user, the Asia Pacific infectious disease diagnostics market is segmented into diagnostic laboratories, hospitals & clinics, research institutes, homecare settings, and others. The diagnostic laboratories segment held 43.4% share of the Asia Pacific infectious disease diagnostics market in 2022, amassing US$ 2,027.33 million. It is projected to garner US$ 3,627.82 million by 2030 to expand at 7.5% CAGR during 2022-2030.

Based on country, the Asia Pacific infectious disease diagnostics market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China held 31.0% share of Asia Pacific infectious disease diagnostics market in 2022, amassing US$ 1,447.24 million. It is projected to garner US$ 2,372.15 million by 2030 to expand at 6.4% CAGR during 2022-2030.

Key players operating in the Asia Pacific infectious disease diagnostics market are Abbott Laboratories, Bruker Corp, Cardinal Health Inc, F. Hoffmann-La Roche Ltd, Trinity Biotech Plc, Danaher Corp, Bio-Rad Laboratories Inc, AccuBioTech Co Ltd, ACON Laboratories Inc, and DiaSorin SpA, among others.


Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com